Effects of clarithromycin on lansoprazole pharmacokinetics betweenCYP2C19genotypes
- 20 January 2005
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (3), 302-309
- https://doi.org/10.1111/j.1365-2125.2004.02329.x
Abstract
Lansoprazole is a substrate of CYP2C19 and CYP3A. The aim of this study was to compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of lansoprazole between CYP2C19 genotypes. A two-way randomized double-blind, placebo-controlled crossover study was performed. Eighteen volunteers, of whom six were homozygous extensive metabolizers (EMs), six were heterozygous EMs and six were poor metabolizers (PMs) for CYP2C19, received two 6-day courses of either clarithromycin 800 mg or placebo daily in a randomized fashion with a single oral dose of lansoprazole 60 mg on day 6 in all cases. Plasma concentrations of lansoprazole and its metabolites, 5-hydroxylansoprazole and lansoprazole sulphone were monitored up to 24 h after dosing. During placebo administration, the mean AUC0, infinity of lansoprazole in homozygous EMs, heterozygous EMs and PMs were 4652 (95% CI, 2294, 7009) ng ml(-1) h, 8299 (4784, 11814) ng ml(-1) h and 25293 (17643, 32943) ng ml(-1) h (P < 0.001), respectively. Clarithromycin treatment significantly increased Cmax by 1.47-fold, 1.71-fold and 1.52-fold and AUC0, infinity of lansoprazole by 1.55-fold, 1.74-fold, and 1.80-fold in these genotype groups, respectively, whereas elimination half-life was prolonged only in PMs. The clarithromycin-mediated percent increase in pharmacokinetic parameters such as Cmax, AUC0, infinity or elimination half-life did not differ between the three CYP2C19 genotypes. The present study indicates that there are significant drug interactions between lansoprazole and clarithromycin in all CYP2C19 genotype groups probably through CYP3A inhibition. The bioavailability of lansoprazole might, to some extent, be increased through inhibition of P-glycoprotein during clarithromycin treatment.Keywords
This publication has 42 references indexed in Scilit:
- STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMESDrug Metabolism and Disposition, 2003
- Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interactionBritish Journal of Clinical Pharmacology, 2003
- Reversal of Anticancer Drug Resistance by Macrolide Antibiotics in Vitro and in VivoClinical and Experimental Pharmacology and Physiology, 2000
- Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazoleBritish Journal of Clinical Pharmacology, 1998
- Pharmacokinetics, Metabolism and Interactions of Acid Pump InhibitorsClinical Pharmacokinetics, 1996
- Gastrointestinal response to foodGut, 1996
- Clinical Pharmacokinetics of LansoprazoleClinical Pharmacokinetics, 1995
- LansoprazoleDrugs, 1994
- The effects of lansoprazole, a new H+,K+‐ATPase inhibitor, on gastric pH and serum gastrinAlimentary Pharmacology & Therapeutics, 1992
- Pharmacokinetic Interactions of the Macrolide AntibioticsClinical Pharmacokinetics, 1985